Serum profiles of insulin-like growth factors and their binding proteins in adults with growth hormone receptor deficiency treated with insulin-like growth factor I.

P. J. Fielder, S. E. Gargosky, M. Vaccarello, K. Wilson, P. Cohen, F. Diamond, J. Guevara-Aguirre, A. L. Rosenbloom, Ronald (Ron) Rosenfeld

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Six adult patients with growth hormone receptor deficiency (GHRD) (2 men, 4 women) with an identical defect in the growth hormone receptor (GHR) gene, were treated with recombinant human insulin-like growth factor I (IGF-I), 40 micrograms/kg s.c. twice daily, for 7 days. Serum concentrations of IGF peptide and IGF binding protein-3 (IGFBP-3) were measured by specific radioimmunoassays; serum IGFBPs were also measured by Western ligand blotting. The size distribution of both IGF-I and IGF-II was measured in serum following size-exclusion fast-performance liquid chromatography. IGF-I treatment resulted in a normalization of serum IGF-I levels on days 1-7 of treatment and a decrease in serum IGF-II levels. The fall in IGF-II levels and the simultaneous rise in IGF-I levels, however, resulted in an unchanged total serum IGF level. The low IGFBP-3 values did not significantly change during treatment, whereas there was a slight increase in IGFBP-2 levels. Preliminary analysis of size-fractionated sera suggested an increase in IGF-I levels in the 40 and 150 kDa regions at the expense of IGF-II levels. The results suggest that despite the failure of IGF-I treatment to increase IGFBPs significantly, serum IGFBP concentrations were sufficient to maintain normal levels of IGF-I.

Original languageEnglish (US)
Pages (from-to)40-43
Number of pages4
JournalActa paediatrica (Oslo, Norway : 1992). Supplement
Volume388
StatePublished - Mar 1993
Externally publishedYes

Fingerprint

Laron Syndrome
Insulin-Like Growth Factor Binding Proteins
Insulin-Like Growth Factor I
Insulin-Like Growth Factor II
Serum
Insulin-Like Growth Factor Binding Protein 3
Insulin-Like Growth Factor Binding Protein 2
Therapeutics
Liquid Chromatography
Radioimmunoassay
Western Blotting
Ligands

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Serum profiles of insulin-like growth factors and their binding proteins in adults with growth hormone receptor deficiency treated with insulin-like growth factor I. / Fielder, P. J.; Gargosky, S. E.; Vaccarello, M.; Wilson, K.; Cohen, P.; Diamond, F.; Guevara-Aguirre, J.; Rosenbloom, A. L.; Rosenfeld, Ronald (Ron).

In: Acta paediatrica (Oslo, Norway : 1992). Supplement, Vol. 388, 03.1993, p. 40-43.

Research output: Contribution to journalArticle

Fielder, PJ, Gargosky, SE, Vaccarello, M, Wilson, K, Cohen, P, Diamond, F, Guevara-Aguirre, J, Rosenbloom, AL & Rosenfeld, RR 1993, 'Serum profiles of insulin-like growth factors and their binding proteins in adults with growth hormone receptor deficiency treated with insulin-like growth factor I.', Acta paediatrica (Oslo, Norway : 1992). Supplement, vol. 388, pp. 40-43.
Fielder, P. J. ; Gargosky, S. E. ; Vaccarello, M. ; Wilson, K. ; Cohen, P. ; Diamond, F. ; Guevara-Aguirre, J. ; Rosenbloom, A. L. ; Rosenfeld, Ronald (Ron). / Serum profiles of insulin-like growth factors and their binding proteins in adults with growth hormone receptor deficiency treated with insulin-like growth factor I. In: Acta paediatrica (Oslo, Norway : 1992). Supplement. 1993 ; Vol. 388. pp. 40-43.
@article{0d9e8e9af8994ebfa5c20a61c9f6c60a,
title = "Serum profiles of insulin-like growth factors and their binding proteins in adults with growth hormone receptor deficiency treated with insulin-like growth factor I.",
abstract = "Six adult patients with growth hormone receptor deficiency (GHRD) (2 men, 4 women) with an identical defect in the growth hormone receptor (GHR) gene, were treated with recombinant human insulin-like growth factor I (IGF-I), 40 micrograms/kg s.c. twice daily, for 7 days. Serum concentrations of IGF peptide and IGF binding protein-3 (IGFBP-3) were measured by specific radioimmunoassays; serum IGFBPs were also measured by Western ligand blotting. The size distribution of both IGF-I and IGF-II was measured in serum following size-exclusion fast-performance liquid chromatography. IGF-I treatment resulted in a normalization of serum IGF-I levels on days 1-7 of treatment and a decrease in serum IGF-II levels. The fall in IGF-II levels and the simultaneous rise in IGF-I levels, however, resulted in an unchanged total serum IGF level. The low IGFBP-3 values did not significantly change during treatment, whereas there was a slight increase in IGFBP-2 levels. Preliminary analysis of size-fractionated sera suggested an increase in IGF-I levels in the 40 and 150 kDa regions at the expense of IGF-II levels. The results suggest that despite the failure of IGF-I treatment to increase IGFBPs significantly, serum IGFBP concentrations were sufficient to maintain normal levels of IGF-I.",
author = "Fielder, {P. J.} and Gargosky, {S. E.} and M. Vaccarello and K. Wilson and P. Cohen and F. Diamond and J. Guevara-Aguirre and Rosenbloom, {A. L.} and Rosenfeld, {Ronald (Ron)}",
year = "1993",
month = "3",
language = "English (US)",
volume = "388",
pages = "40--43",
journal = "Acta Paediatrica, International Journal of Paediatrics, Supplement",
issn = "0803-5326",
publisher = "Taylor and Francis Ltd.",

}

TY - JOUR

T1 - Serum profiles of insulin-like growth factors and their binding proteins in adults with growth hormone receptor deficiency treated with insulin-like growth factor I.

AU - Fielder, P. J.

AU - Gargosky, S. E.

AU - Vaccarello, M.

AU - Wilson, K.

AU - Cohen, P.

AU - Diamond, F.

AU - Guevara-Aguirre, J.

AU - Rosenbloom, A. L.

AU - Rosenfeld, Ronald (Ron)

PY - 1993/3

Y1 - 1993/3

N2 - Six adult patients with growth hormone receptor deficiency (GHRD) (2 men, 4 women) with an identical defect in the growth hormone receptor (GHR) gene, were treated with recombinant human insulin-like growth factor I (IGF-I), 40 micrograms/kg s.c. twice daily, for 7 days. Serum concentrations of IGF peptide and IGF binding protein-3 (IGFBP-3) were measured by specific radioimmunoassays; serum IGFBPs were also measured by Western ligand blotting. The size distribution of both IGF-I and IGF-II was measured in serum following size-exclusion fast-performance liquid chromatography. IGF-I treatment resulted in a normalization of serum IGF-I levels on days 1-7 of treatment and a decrease in serum IGF-II levels. The fall in IGF-II levels and the simultaneous rise in IGF-I levels, however, resulted in an unchanged total serum IGF level. The low IGFBP-3 values did not significantly change during treatment, whereas there was a slight increase in IGFBP-2 levels. Preliminary analysis of size-fractionated sera suggested an increase in IGF-I levels in the 40 and 150 kDa regions at the expense of IGF-II levels. The results suggest that despite the failure of IGF-I treatment to increase IGFBPs significantly, serum IGFBP concentrations were sufficient to maintain normal levels of IGF-I.

AB - Six adult patients with growth hormone receptor deficiency (GHRD) (2 men, 4 women) with an identical defect in the growth hormone receptor (GHR) gene, were treated with recombinant human insulin-like growth factor I (IGF-I), 40 micrograms/kg s.c. twice daily, for 7 days. Serum concentrations of IGF peptide and IGF binding protein-3 (IGFBP-3) were measured by specific radioimmunoassays; serum IGFBPs were also measured by Western ligand blotting. The size distribution of both IGF-I and IGF-II was measured in serum following size-exclusion fast-performance liquid chromatography. IGF-I treatment resulted in a normalization of serum IGF-I levels on days 1-7 of treatment and a decrease in serum IGF-II levels. The fall in IGF-II levels and the simultaneous rise in IGF-I levels, however, resulted in an unchanged total serum IGF level. The low IGFBP-3 values did not significantly change during treatment, whereas there was a slight increase in IGFBP-2 levels. Preliminary analysis of size-fractionated sera suggested an increase in IGF-I levels in the 40 and 150 kDa regions at the expense of IGF-II levels. The results suggest that despite the failure of IGF-I treatment to increase IGFBPs significantly, serum IGFBP concentrations were sufficient to maintain normal levels of IGF-I.

UR - http://www.scopus.com/inward/record.url?scp=0027564596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027564596&partnerID=8YFLogxK

M3 - Article

C2 - 7687170

AN - SCOPUS:0027564596

VL - 388

SP - 40

EP - 43

JO - Acta Paediatrica, International Journal of Paediatrics, Supplement

JF - Acta Paediatrica, International Journal of Paediatrics, Supplement

SN - 0803-5326

ER -